FLOW - Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease

Brief description of study

This study is looking at how well a new medicine called semaglutide can treat chronic kidney disease in people with type 2 diabetes compared to a placebo which looks like semaglutide, but has no effect on the body. The research will see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes.

Clinical Study Identifier: s19-00444
ClinicalTrials.gov Identifier: NCT03819153
Principal Investigator: Naveed N. Masani
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.